I can start with the points about independent evaluation.
First of all, there are my suggestions about who does the trials, who analyzes them, and whether or not these are the trials that would be required. The second point about independent analysis is that, even with all of the best intentions, people make mistakes when they're analyzing trials. Health Canada does. Independent researchers do. I think you need full disclosure, as was said, of the clinical trial reports. Once a drug is on the market, people can go back to that kind of information, look at it, and see whether or not they think that the right decisions were made. Perhaps they could analyze that information in different ways and point out things that weren't apparent to the people who initially did the analysis.
I think these two things are complementary.